National Security Commission on Emerging Biotechnology Urges Department of State and Department of Commerce to Expedite Innovative Research Collaboration with Japan
10 April 2024
Read the Full Letter Here [pdf]
FOR IMMEDIATE RELEASE
Washington, DC – Yesterday, the National Security Commission on Emerging Biotechnology sent a letter to the leadership of the Department of State and the Department of Commerce encouraging the U.S. Government to work more closely with the Government of Japan to invest in and develop emerging biotechnology.
On the occasion of Prime Minister Kishida Fumio’s state visit to the United States, Commissioners highlighted their recent official visit to Japan, noting that the Government of Japan has prioritized investments into critical and emerging technologies, including biotechnology. While in Japan, the delegation met with U.S. government officials, Japanese government agencies, and others to learn about the current landscape of biotechnology in Japan and discuss opportunities for greater collaboration.
The Commission maintains that “closer cooperation on biotechnology can strengthen supply chains, make manufacturing more efficient and sustainable, and expedite innovative research” and urges the Departments of State and Commerce to move swiftly to further strengthen the U.S. relationship with Japan.
About NSCEB: The National Security Commission on Emerging Biotechnology is a Congressionally mandated commission whose purpose is to advance and secure biotechnology, biomanufacturing, and associated technologies for U.S. national security and to prepare the United States for the age of biotechnology. The Commission is a legislative branch advisory entity and submitted an interim report to the President and the Armed Services Committees in December 2023 and will submit a final report in early 2025, including recommendations for action by Congress and the federal government. The bipartisan Commission is composed of twelve Commissioners with members from both the Senate and the House of Representatives as well as experts from industry, academia, and government. For more information about the Commission, visit https://biotech.senate.gov.
